Magnetic Resonance Imaging of the Tumor Microenvironment in Radiotherapy: Perfusion, Hypoxia, and Metabolism

Seminars in Radiation Oncology

Volumn 24, Issue 3, 2014, Pages 210-217

  Matsuo, Masayuki ^a   Matsumoto, Shingo ^a   Mitchell, James B ^a   Krishna, Murali C ^a   Camphausen, Kevin ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 13;

CONTRAST ENHANCEMENT; ELECTRON SPIN RESONANCE; GLYCOLYSIS; HUMAN; HYPOXIA; METABOLISM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXYGEN TENSION; PERFUSION; PRIORITY JOURNAL; RADIOTHERAPY; REVIEW; TISSUE METABOLISM; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; ANIMAL; CELL HYPOXIA; COMPUTER ASSISTED RADIOTHERAPY; IMAGE GUIDED RADIOTHERAPY; NEOPLASMS; ONCOLOGY; PH; PROCEDURES;

ANIMALS; CELL HYPOXIA; ELECTRON SPIN RESONANCE SPECTROSCOPY; HUMANS; HYDROGEN-ION CONCENTRATION; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; NEOPLASMS; RADIATION ONCOLOGY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, IMAGE-GUIDED; TUMOR MICROENVIRONMENT;

EID: 84902163612     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2014.02.002     Document Type: Review

References (39)

1. Horsman M.R., Nordsmark M., Overgaard J. Techniques to assess the oxygenation of human tumors. State of the art. Strahlenther Onkol 1998, 174(suppl 4):2-5.
2. Stratford I.J., Adams G.E., Bremner J.C., et al. Manipulation and exploitation of the tumour environment for therapeutic benefit. Int J Radiat Biol 1994, 65:85-94.
3. Chaplin D.J., Olive P.L., Durand R.E. Intermittent blood flow in a murine tumor: Radiobiological effects. Cancer Res 1987, 47:597-601.
4. Dewhirst M.W. Relationships between cycling hypoxia, HIF-1, angiogenesis and oxidative stress. Radiat Res 2009, 172:653-665.
5. Matsumoto S., Yasui H., Mitchell J.B., Krishna M.C. Imaging cycling tumor hypoxia. Cancer Res 2010, 70:10019-10023.
6. Yasui H., Matsumoto S., Devasahayam N., et al. Low-field magnetic resonance imaging to visualize chronic and cycling hypoxia in tumor-bearing mice. Cancer Res 2010, 70:6427-6436.
7. Dewhirst M.W. Intermittent hypoxia furthers the rationale for hypoxia-inducible factor-1 targeting. Cancer Res 2007, 67:854-855.
8. Thomlinson R.H., Gray L.H. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955, 9:539-549.
9. Gatenby R.A., Gillies R.J. Why do cancers have high aerobic glycolysis?. Nat Rev Cancer 2004, 4:891-899.
10. Kim J.W., Tchernyshyov I., Semenza G.L., Dang C.V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006, 3:177-185.
11. Gillies R.J., Gatenby R.A. Adaptive landscapes and emergent phenotypes: Why do cancers have high glycolysis?. J Bioenerg Biomembr 2007, 39:251-257.
12. Tatum J.L., Kelloff G.J., Gillies R.J., et al. Hypoxia: Importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 2006, 82:699-757.
13. Brown J.M., Wilson W.R. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004, 4:437-447.
14. Grau C., Muren L.P., Hoyer M., et al. Image-guided adaptive radiotherapy-Integration of biology and technology to improve clinical outcome. Acta Oncol 2008, 47:1182-1185.
15. Grau C., Olsen D.R., Overgaard J., et al. Biology-guided adaptive radiation therapy-Presence or future?. Acta Oncol 2010, 49:884-887.
16. Krishna M.C., Matsumoto S., Saito K., et al. Magnetic resonance imaging of tumor oxygenation and metabolic profile. Acta Oncol 2013, 52:1248-1256.
17. Horsman M.R., Mortensen L.S., Petersen J.B., et al. Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol 2012, 9:674-687.
18. Cooper R.A., Carrington B.M., Loncaster J.A., et al. Tumour oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix. Radiother Oncol 2000, 57:53-59.
19. Mayr N.A., Yuh W.T., Magnotta V.A., et al. Tumor perfusion studies using fast magnetic resonance imaging technique in advanced cervical cancer: A new noninvasive predictive assay. Int J Radiat Oncol Biol Phys 1996, 36:623-633.
20. Yamashita Y., Baba T., Baba Y., et al. Dynamic contrast-enhanced MR imaging of uterine cervical cancer: Pharmacokinetic analysis with histopathologic correlation and its importance in predicting the outcome of radiation therapy. Radiology 2000, 216:803-809.
21. Loncaster J.A., Carrington B.M., Sykes J.R., et al. Prediction of radiotherapy outcome using dynamic contrast enhanced MRI of carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2002, 54:759-767.
22. Mayr N.A., Wang J.Z., Zhang D., et al. Longitudinal changes in tumor perfusion pattern during the radiation therapy course and its clinical impact in cervical cancer. Int J Radiat Oncol Biol Phys 2009, 77:502-508.
23. Andersen E.K., Hole K.H., Lund K.V., et al. Dynamic contrast-enhanced MRI of cervical cancers: Temporal percentile screening of contrast enhancement identifies parameters for prediction of chemoradioresistance. Int J Radiat Oncol Biol Phys 2011, 82:e485-e492.
24. Halle C., Andersen E., Lando M., et al. Hypoxia-induced gene expression in chemoradioresistant cervical cancer revealed by dynamic contrast-enhanced MRI. Cancer Res 2012, 72:5285-5295.
25. Zhao D., Jiang L., Hahn E.W., Mason R.P. Tumor physiologic response to combretastatin A4 phosphate assessed by MRI. Int J Radiat Oncol Biol Phys 2005, 62:872-880.
26. Pacheco-Torres J., Lopez-Larrubia P., Ballesteros P., Cerdán S. Imaging tumor hypoxia by magnetic resonance methods. NMR Biomed 2011, 24:1-16.
27. Hoskin P.J., Carnell D.M., Taylor N.J., et al. Hypoxia in prostate cancer: Correlation of BOLD-MRI with pimonidazole immunohistochemistry-initial observations. Int J Radiat Oncol Biol Phys 2007, 68:1065-1071.
28. 2) inside tumors?. Magn Reson Med 2002, 48:980-986.
29. *2: The case of insulin and NS-398, two inhibitors of oxygen consumption. Magn Reson Med 2006, 56:637-643.
30. 2 and relevance to tumor radiation response. Magn Reson Med 2013, (in press). doi:10.1002/mrm.24846.
31. Matsumoto S., Hyodo F., Subramanian S., et al. Low-field paramagnetic resonance imaging of tumor oxygenation and glycolytic activity in mice. J Clin Invest 2008, 118:1965-1973.
32. 2 determination. Magn Reson Med 2006, 55:1157-1163.
33. Saito K., Matsumoto S., Yasui H., et al. Longitudinal imaging studies of tumor microenvironment in mice treated with the mTOR inhibitor rapamycin. PLoS One 2012, 7:e49456.
34. Ardenkjaer-Larsen J.H., Laursen I., Leunbach I., et al. EPR and DNP properties of certain novel single electron contrast agents intended for oximetric imaging. J Magn Reson 1998, 133:1-12.
35. Matsumoto S., Batra S., Saito K., et al. Antiangiogenic agent sunitinib transiently increases tumor oxygenation and suppresses cycling hypoxia. Cancer Res 2011, 71:6350-6359.
36. Ardenkjaer-Larsen J.H., Fridlund B., Gram A., et al. Increase in signal-to-noise ratio of >10,000 times in liquid-state NMR. Proc Natl Acad Sci U S A 2003, 100:10158-10163.
37. Golman K., Ardenkjaer-Larsen J.H., Petersson J.S., et al. Molecular imaging with endogenous substances. Proc Natl Acad Sci U S A 2003, 100:10435-10439.
38. 13C lactate, pyruvate, and alanine: Noninvasive biomarkers for prostate cancer detection and grading. Cancer Res 2008, 68:8607-8615.
39. 13C magnetic resonance spectroscopic imaging. Magn Reson Med 2011, 65:557-563.